中华普通外科杂志
中華普通外科雜誌
중화보통외과잡지
CHINESE JOURNAL OF GENERAL SURGERY
2013年
1期
35-38
,共4页
乳腺肿瘤%复发%受体,雌激素
乳腺腫瘤%複髮%受體,雌激素
유선종류%복발%수체,자격소
Breast neoplasms%Recurrence%Receptors,estrogen
目的 研究不同激素受体(hormone receptor,HR)状态的乳腺癌患者术后复发风险时间分布特征.方法 回顾性研究北京肿瘤医院乳腺中心自1999年12月-2006年4月手术的1099例原发性乳腺癌患者激素受体状态的复发风险曲线模式.结果 所有患者均获得随访,中位随访时间60.6个月,1099例患者中171例复发.激素受体阴性(hormone receptor-negative,HR-)的乳腺癌患者,在术后第12个月出现第一个复发高峰,54个月左右出现第二个复发高峰.激素受体阳性(hormone receptor-positive,HR+)患者的第一峰在36个月出现,峰值较低且上升较缓和,约在54个月出现第二高峰,随后激素受体阳性肿瘤患者复发风险曲线高于激素受体阴性者.淋巴结阳性(lymphnode-positive,LN+)组与阴性(lymph node-negative,LN-)组在HR-组与HR+组有类似的复发风险曲线模式,淋巴结转移越多复发风险越高.HR+组中LN+亚组复发风险峰值高于LN-亚组2～3倍,HR-组中LN+亚组复发风险峰值高于LN-亚组3～4倍.HR(+)组无复发生存率高于HR(-)组(P＜0.01). 结论 HR+组乳腺癌术后54个月时复发风险高于HR-组,HR+组中LN+患者复发风险高于LN-者.
目的 研究不同激素受體(hormone receptor,HR)狀態的乳腺癌患者術後複髮風險時間分佈特徵.方法 迴顧性研究北京腫瘤醫院乳腺中心自1999年12月-2006年4月手術的1099例原髮性乳腺癌患者激素受體狀態的複髮風險麯線模式.結果 所有患者均穫得隨訪,中位隨訪時間60.6箇月,1099例患者中171例複髮.激素受體陰性(hormone receptor-negative,HR-)的乳腺癌患者,在術後第12箇月齣現第一箇複髮高峰,54箇月左右齣現第二箇複髮高峰.激素受體暘性(hormone receptor-positive,HR+)患者的第一峰在36箇月齣現,峰值較低且上升較緩和,約在54箇月齣現第二高峰,隨後激素受體暘性腫瘤患者複髮風險麯線高于激素受體陰性者.淋巴結暘性(lymphnode-positive,LN+)組與陰性(lymph node-negative,LN-)組在HR-組與HR+組有類似的複髮風險麯線模式,淋巴結轉移越多複髮風險越高.HR+組中LN+亞組複髮風險峰值高于LN-亞組2～3倍,HR-組中LN+亞組複髮風險峰值高于LN-亞組3～4倍.HR(+)組無複髮生存率高于HR(-)組(P＜0.01). 結論 HR+組乳腺癌術後54箇月時複髮風險高于HR-組,HR+組中LN+患者複髮風險高于LN-者.
목적 연구불동격소수체(hormone receptor,HR)상태적유선암환자술후복발풍험시간분포특정.방법 회고성연구북경종류의원유선중심자1999년12월-2006년4월수술적1099례원발성유선암환자격소수체상태적복발풍험곡선모식.결과 소유환자균획득수방,중위수방시간60.6개월,1099례환자중171례복발.격소수체음성(hormone receptor-negative,HR-)적유선암환자,재술후제12개월출현제일개복발고봉,54개월좌우출현제이개복발고봉.격소수체양성(hormone receptor-positive,HR+)환자적제일봉재36개월출현,봉치교저차상승교완화,약재54개월출현제이고봉,수후격소수체양성종류환자복발풍험곡선고우격소수체음성자.림파결양성(lymphnode-positive,LN+)조여음성(lymph node-negative,LN-)조재HR-조여HR+조유유사적복발풍험곡선모식,림파결전이월다복발풍험월고.HR+조중LN+아조복발풍험봉치고우LN-아조2～3배,HR-조중LN+아조복발풍험봉치고우LN-아조3～4배.HR(+)조무복발생존솔고우HR(-)조(P＜0.01). 결론 HR+조유선암술후54개월시복발풍험고우HR-조,HR+조중LN+환자복발풍험고우LN-자.
Objective To study the time distribution of recurrence for postoperative breast cancer patients by hormone receptor status.Methods The characteristics of recurrence in 1099 breast cancer patients with different hormone receptor status undergoing surgery between December 1999 and April 2006 were analyzed retrospectively.Results For those 1099 patients the median follow-up time was 60.6 months.Recurrence was found in 171 patients.For hormone receptor-negative (HRN) patients the first peak of recurrence appeared at the 12th month and the second at about the 54th month.For hormone receptor-positive (HRP) patients the peak of recurrence appeared at the 36th month and a second peak at about the 54th month,and beyond 54 months the hazard was higher for hormone receptor-positive patients.The risk of recurrence was higher with more nodes involved.Node-positive HRP patients suffered two to three times higher risk of recurrence than node-negative HRP patients.Node-positive HRN patients had three to four times higher risk of recurrence than node-negative HRN patients.The recurrence-free survival in HRP patients was higher than that in HRN patients,also the recurrence-free survival in node-negative HRP patients was higher than that in node-positive patients (all P ＜ 0.01).Conclusions The recurrence risk for HRP breast cancer patients was higher than that in HRN patients after 54 months postoperatively.The risk of recurrence for node-positive breast cancer patients was higher than that for HRP node-negatives.
